-
公开(公告)号：US07622585B2
公开(公告)日：2009-11-24
申请号：US11328479
申请日：2006-01-09
IPC分类号： C07D215/38
CPC分类号： C07D401/12 , C07D207/14
摘要： The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it0 is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
摘要翻译： 本发明一般涉及抑制丝氨酸蛋白酶的苯基甘氨酰胺衍生物。 特别涉及可用作凝血级联丝氨酸蛋白酶的选择性抑制剂的新型苯基甘氨酰胺衍生物及其类似物; 例如凝血酶，因子VIIa，因子Xa，因子XIa，因子IXa和/或血浆激肽释放酶。 特别地，它涉及作为因子VIIa抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物及其使用方法。
-
2.发明授权Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants 有权苯基甘氨酰胺和吡啶基甘氨酰胺衍生物可用作抗凝剂公开(公告)号：US07456195B2
公开(公告)日：2008-11-25
申请号：US11472845
申请日：2006-06-22
IPC分类号： A61K31/472 , A61K31/4725 , C07D217/14 , C07D217/24 , A61P7/02 , A61K31/444 , A61K31/502 , A61K31/5025 , C07D401/12 , C07D237/34 , C07F5/02 , C07F5/04 , C07F7/04 , A61P9/10
CPC分类号： C07K5/06078 , A61K38/00 , C07D217/22 , C07D237/34 , C07D401/12 , C07K5/06191
摘要： The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.
摘要翻译： 本发明提供式（I）或（IV）的新型苯基甘氨酰胺衍生物：或其立体异构体，互变异构体，药学上可接受的盐，溶剂合物或前药，其中变量W，W 1，Y， Z，R 7，R 8，R 9和R 11如本文所定义。 这些化合物是可用作药物的因子VIIa的选择性抑制剂。
-
3.发明申请Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants 有权苯基甘氨酰胺和吡啶基甘氨酰胺衍生物可用作抗凝剂公开(公告)号：US20070003539A1
公开(公告)日：2007-01-04
申请号：US11472845
申请日：2006-06-22
申请人： Xiaojun Zhang , Alexandra Nirschl , Yan Zou , Eldon Priestley
发明人： Xiaojun Zhang , Alexandra Nirschl , Yan Zou , Eldon Priestley
IPC分类号： A61K38/48
CPC分类号： C07K5/06078 , A61K38/00 , C07D217/22 , C07D237/34 , C07D401/12 , C07K5/06191
摘要： The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.
摘要翻译： 本发明提供式（I）或（IV）的新型苯基甘氨酰胺衍生物：或其立体异构体，互变异构体，药学上可接受的盐，溶剂合物或前药，其中变量W，W 1，Y， Z，R 7，R 8，R 9和R 11如本文所定义。 这些化合物是可用作药物的因子VIIa的选择性抑制剂。
-
公开(公告)号：US20060166997A1
公开(公告)日：2006-07-27
申请号：US11328479
申请日：2006-01-09
申请人： Xiaojun Zhang , Eldon Priestley , Alexandra Nirschl , Yan Zou
发明人： Xiaojun Zhang , Eldon Priestley , Alexandra Nirschl , Yan Zou
IPC分类号： A61K31/517 , A61K31/502 , A61K31/4745 , A61K31/4709
CPC分类号： C07D401/12 , C07D207/14
摘要： The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
-
公开(公告)号：US07625923B2
公开(公告)日：2009-12-01
申请号：US11070808
申请日：2005-03-02
申请人： Alexandra Nirschl , James C. Sutton , Lawrence Hamann , Tammy Wang , Yan Zou , Chongqing Sun
发明人： Alexandra Nirschl , James C. Sutton , Lawrence Hamann , Tammy Wang , Yan Zou , Chongqing Sun
IPC分类号： A61K31/4745 , C07D491/02
CPC分类号： C07D487/04 , C07D498/04 , C07D513/04
摘要： The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X, Y and n are defined herein.
摘要翻译： 本发明涉及式I的双环化合物，含有这些化合物的药物组合物和使用这些化合物治疗雄激素受体相关病症如年龄相关疾病，例如肌肉减少症的方法，其中R1，R2，R5 ，X，Y和n如本文所定义。
-
公开(公告)号：US20050197359A1
公开(公告)日：2005-09-08
申请号：US11070808
申请日：2005-03-02
申请人： Alexandra Nirschl , James Sutton , Lawrence Hamann , Tammy Wang , Yan Zou , Chongqing Sun
发明人： Alexandra Nirschl , James Sutton , Lawrence Hamann , Tammy Wang , Yan Zou , Chongqing Sun
IPC分类号： A61K31/424 , A61K31/425 , A61K31/428 , A61K31/44 , A61K31/4745 , C07D263/60 , C07D471/02 , C07D491/02 , C07D498/02
CPC分类号： C07D487/04 , C07D498/04 , C07D513/04
摘要： The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X, Y and n are defined herein.
摘要翻译： 本发明涉及式I的双环化合物，含有这些化合物的药物组合物和使用这些化合物治疗雄激素受体相关病症例如年龄相关疾病，例如肌肉减少症的方法，其中R 1 R 2，R 5，X，Y和n在本文中定义。
-
公开(公告)号：US20120271177A1
公开(公告)日：2012-10-25
申请号：US13432619
申请日：2012-03-28
IPC分类号： A61B5/0205 , A61B7/00 , A61B5/02
CPC分类号： A61B5/0538 , A61B5/0031 , A61B5/0205 , A61B5/0215 , A61B5/029 , A61B5/7239 , A61B7/00 , A61N1/3622 , A61N1/3627 , A61N1/36521 , A61N1/36542 , A61N1/37247 , A61N1/37258 , A61N1/37282 , G16H50/50
摘要： A patient-specific model can show changes in cardiac stroke volume or cardiac output, such as to predict heart failure or to indicate cardiac remodeling. The patient-specific model can be derived from a surrogate indication of a cardiac stroke volume, such as a physical activity level, and features obtained from a thoracic impedance waveform, such as mean or peak-to-peak impedance values. In an example, several models corresponding to different patient physical activity levels can be determined.
摘要翻译： 患者特异性模型可以显示心脏搏动量或心输出量的变化，例如预测心力衰竭或指示心脏重构。 患者特异性模型可以从心脏搏动体积的替代指示（例如身体活动水平）和从胸部阻抗波形（例如平均值或峰 - 峰值阻抗值）获得的特征得到。 在一个示例中，可以确定对应于不同患者身体活动水平的几个模型。
-
-
-
公开(公告)号：US09295405B2
公开(公告)日：2016-03-29
申请号：US13432619
申请日：2012-03-28
IPC分类号： A61B5/08 , A61B5/053 , A61B5/0205 , A61B5/029 , A61N1/365 , A61N1/372 , A61N1/362 , A61B7/00 , A61B5/00 , A61B5/0215
CPC分类号： A61B5/0538 , A61B5/0031 , A61B5/0205 , A61B5/0215 , A61B5/029 , A61B5/7239 , A61B7/00 , A61N1/3622 , A61N1/3627 , A61N1/36521 , A61N1/36542 , A61N1/37247 , A61N1/37258 , A61N1/37282 , G16H50/50
摘要： A patient-specific model can show changes in cardiac stroke volume or cardiac output, such as to predict heart failure or to indicate cardiac remodeling. The patient-specific model can be derived from a surrogate indication of a cardiac stroke volume, such as a physical activity level, and features obtained from a thoracic impedance waveform, such as mean or peak-to-peak impedance values. In an example, several models corresponding to different patient physical activity levels can be determined.
摘要翻译： 患者特异性模型可以显示心脏搏动量或心输出量的变化，例如预测心力衰竭或指示心脏重构。 患者特异性模型可以从心脏搏动体积的替代指示（例如身体活动水平）和从胸部阻抗波形（例如平均值或峰 - 峰值阻抗值）获得的特征得到。 在一个示例中，可以确定对应于不同患者身体活动水平的几个模型。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.033 秒)
